FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

Guide BCG-Unresponsive Bladder Cancer Drugs

Federal Register notice: FDA makes available a draft guidance entitled Bacillus Calmette-Gurin-Unresponsive Nonmuscle Invasive Bladder Cancer: Develop...

latest-news-card-1
Human Drugs

Hold Lifted on Fabry Cardiomyopathy Therapy

FDA lifts a clinical hold against 4D Molecular Therapeutics 4D-310 therapy being studied for treating Fabry disease cardiomyopathy.

latest-news-card-1
Federal Register

Panel to Mull Clozapine REMS Potential Changes

Federal Register notice: FDA announces an 11/19 advisory committee meeting to discuss potential changes to the clozapine risk evaluation and mitigatio...

latest-news-card-1
Human Drugs

4 Observations on Imprimis FDA-483

FDA releases the form FDA-483 with four observations from an inspection at the Ledgewood, NJ-based Imprimis NJOF outsourcing facility.

latest-news-card-1

Stakeholder Comments on FDA BIMO Guidance

Four stakeholders give FDA general and specific recommendations on a draft guidance on bioresearch monitoring inspection processes and practices.

latest-news-card-1
Human Drugs

Oncologic Drug Dosage Guidance

FDA publishes a guidance on optimizing dosage for oncologic drug and biologic therapies.

latest-news-card-1
Human Drugs

Amneal Gets Approval for Parkinsons Drug

FDA approves an Amneal Pharmaceuticals NDA for Crexont (carbidopa and levodopa) extended-release capsules for treating Parkinsons disease.

latest-news-card-1
Federal Register

Cipro 100mg Withdrawn Due to Safety/Efficacy: FDA

Federal Register notice: FDA determines that Bayers Cipro (ciprofloxacin HCl) tablet, equivalent to 100 mg base, was withdrawn from sale due to safety...

latest-news-card-1
Federal Register

Drug Experiential Learning Site Visits for FY 2025

Federal Register notice: FDA announces its fiscal year 2025 CDER Office of Pharmaceutical Quality Experiential Learning Site Visit Program.

Human Drugs

Accelerated Approval for Novartis Fabhalta

FDA gives accelerated approval to Novartis Fabhalta for reducing proteinuria in primary IgA nephropathy.